Management of the Axila

被引：10

作者：

Amersi, Farin ^{[1
]}

Giuliano, Armando E. ^{[1
]}

机构：

[1] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Saul & Joyce Brandman Breast Ctr, Dept Surg,Div Surg Oncol, Los Angeles, CA 90048 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2013年 / 27卷 / 04期

关键词：

Axillary node dissection; Sentinel lymph node biopsy; ACOSOG Z0010; ACOSOG Z0011; SENTINEL LYMPH-NODE; BREAST-CANCER PATIENTS; NEOADJUVANT CHEMOTHERAPY; PREOPERATIVE CHEMOTHERAPY; AXILLARY DISSECTION; PROPHYLACTIC MASTECTOMY; RANDOMIZED-TRIAL; PERITUMORAL INJECTION; TUMOR SIZE; FOLLOW-UP;

D O I：

10.1016/j.hoc.2013.05.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The development and wide acceptance of sentinel lymph node biopsy (SLNB) has profoundly affected the management of breast cancer. SLNB has spared the additional morbidity of axillary lymph node dissection (ALND) without compromising diagnostic accuracy and prognostic information in patients with clinically node-negative early-stage breast cancer. It has become an invaluable tool to clinicians to guide decisions regarding adjuvant treatment. The management of breast cancer continues to advance to more minimally invasive approaches, and the role of ALND is likely to become less important in the future.

引用

页码：687 / +

页数：17

共 88 条

[1] Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer [J].

Abrial, C ;

Van Praagh, I ;

Delva, R ;

Leduc, B ;

Fleury, J ;

Gamelin, E ;

Sillet-Bach, I ;

Penault-Llorca, F ;

Amat, S ;

Chollet, P .

ONCOLOGIST, 2005, 10 (04) :242-249

[2] Lymphatic mapping and sentinel node biopsy in the patient with breast cancer [J].

Albertini, JJ ;

Lyman, GH ;

Cox, C ;

Yeatman, T ;

Balducci, L ;

Ku, NN ;

Shivers, S ;

Berman, C ;

Wells, K ;

Rapaport, D ;

Shons, A ;

Horton, J ;

Greenberg, H ;

Nicosia, S ;

Clark, R ;

Cantor, A ;

Reintgen, DS .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (22) :1818-1822

[3] Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer [J].

Beenken, SW ;

Urist, MM ;

Zhang, YT ;

Desmond, R ;

Krontiras, H ;

Medina, H ;

Bland, KI .

ANNALS OF SURGERY, 2003, 237 (05) :732-738

[4] Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer [J].

Burak, WE ;

Hollenbeck, ST ;

Zervos, EE ;

Hock, KL ;

Kemp, LC ;

Young, DC .

AMERICAN JOURNAL OF SURGERY, 2002, 183 (01) :23-27

[5]

CABANAS RM, 1977, CANCER-AM CANCER SOC, V39, P456, DOI 10.1002/1097-0142(197702)39:2<456::AID-CNCR2820390214>3.0.CO

[6]

2-I

[7] Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma - Effective clinical downstaging allows breast preservation and predicts outstanding local control and survival [J].

Cance, WG ;

Carey, LA ;

Calvo, BF ;

Sartor, C ;

Sawyer, L ;

Moore, DT ;

Rosenman, J ;

Ollila, DW ;

Graham, M .

ANNALS OF SURGERY, 2002, 236 (03) :295-303

[8]

CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO

[9]

2-H

[10]

CHIAPPA S, 1966, SURG GYNECOL OBSTETR, V123, P10

← 1 2 3 4 5 6 7 8 9 →